Protalix BioTherapeutics, Inc. has completed a private stock placement
Protalix BioTherapeutics, Inc. has raised funds to refinance the company for further development.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received the approval of the US Food and Drug Administration, for the treatment of Gaucher disease.
Oaklins’ team in Israel advised Protalix BioTherapeutics, Inc. and acted as a member in the distributors’ consortium.
Talk to the deal team
PrincipalTel Aviv, Israel
PartnerTel Aviv, Israel
SupportTel Aviv, Israel
Navitas Petroleum has issued bonds worth US$117 million
Navitas Petroleum has completed a fundraising to to refinance and develop the company.Learn more
Laptaria cu Caimac has raised growth capital
Laptaria cu Caimac has raised US$3.5 million via a corporate bond private placement that has attracted strong interest both from high-net-worth individuals and institutional investors.Learn more
Global Media Santé has been acquired by SFP Expansion
Global Media Santé’s CEO, Alain Trébucq, and Apax Partners have sold the company to SFP Expansion Group.Learn more